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Trends
Genome-wide association studies
(GWASs) have highlighted genetic var-
iants in the CHRNA5–CHRNA3–
CHRB4 gene cluster associated with
smoking heaviness and nicotine
dependence as well as known smok-
ing-related diseases such as chronic
obstructive pulmonary disease (COPD)
and lung cancer.
Animal studies have described the
anatomy and function of the nicotinic
acetylcholine receptor (nAChR) subu-
nits encoded by the CHRNA5–
CHRNA3–CHRB4 gene cluster.
More in-depth phenotyping in humans
is improving our understanding of how
these variants contribute to smoking
behaviour.
Use of this gene cluster in Mendelian
randomisation analyses is enabling us
to investigate the causal effects of
tobacco use. The latest ﬁndings sug-
gest that smoking heaviness could be a
causal factor for schizophrenia.
Validated genetic targets emerging
from GWASs that inﬂuence smoking
behaviour may pave the way towards
individually tailored smoking cessation
treatments, ultimately reducing the
burden of smoking-related diseases.
1UK Centre for Tobacco and Alcohol
Studies, School of Experimental
Psychology, University of Bristol,
Bristol, UK
2Oncology Translational Medicine Unit,
Early Clinical Development,
AstraZeneca, Cambridge, UKReview
The CHRNA5–A3–B4 Gene
Cluster and Smoking: From
Discovery to Therapeutics
Glenda Lassi,1,2,* Amy E. Taylor,1,3 Nicholas J. Timpson,3
Paul J. Kenny,4 Robert J. Mather,5 Tim Eisen,2,6 and
Marcus R. Munafò1,3
Genome-wide association studies (GWASs) have identiﬁed associations
between the CHRNA5–CHRNA3–CHRNB4 gene cluster and smoking
heaviness and nicotine dependence. Studies in rodents have described the
anatomical localisation and function of the nicotinic acetylcholine receptors
(nAChRs) formed by the subunits encoded by this gene cluster. Further inves-
tigations that complemented these studies highlighted the variability of indi-
viduals’ smoking behaviours and their ability to adjust nicotine intake. GWASs
of smoking-related health outcomes have also identiﬁed this signal in the
CHRNA5–CHRNA3–CHRNB4 gene cluster. This insight underpins approaches
to strengthen causal inference in observational data. Combining genetic and
mechanistic studies of nicotine dependence and smoking heaviness may
reveal novel targets for medication development. Validated targets can inform
genetic therapeutic interventions for smoking cessation and tobacco-related
diseases.
Genetic Variants and Smoking Behaviours
GWASs (see Glossary) seek to identify genetic variants associated with speciﬁc phenotypes,
and cigarette smoking is a complex behavioural phenotype that has successfully been
subjected to this approach (Figure 1A, Key Figure). An association between the SNP
rs16969968 in CHRNA5 and nicotine dependence was ﬁrst reported in 2007 in a candidate
gene study [1]. The following year rs1051730 at the same locus (in CHRNA3 but strongly
correlated with rs16969968 in samples of European ancestry) was found to be associated with
smoking quantity in a GWAS [2]. This study also reported an association between rs1051730
and two smoking-related diseases: lung cancer and peripheral arterial disease. Importantly,
CHRNA5 was not recognised as a strong candidate gene at the time given the then-known
neurobiology of tobacco dependence. Animal models had implicated the /4 and b2 nicotinic
receptor subunits as critical to nicotine's reinforcing effects [3,4], and /4b2* partial agonists
are one of the most effective treatments available for smoking cessation [5]. Therefore, while
the candidate gene study was published ﬁrst, the GWAS (which did not require a strong prior
hypothesis regarding gene selection) made the greater impact. What followed illustrates the
potential for GWASs to advance our understanding of neurobiology in a way that hypothesis-
driven investigations such as candidate gene studies (which rely on known or presumed
neurobiology) rarely could. These ﬁndings have made variants in the CHRNA5–CHRNA3–
CHRNB4 region promising targets for the study of nicotine dependence and smoking
heaviness, given their association with response to nicotine and its consequent consumption
and titration.Trends in Neurosciences, December 2016, Vol. 39, No. 12 http://dx.doi.org/10.1016/j.tins.2016.10.005 851
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Key Figure
From Nicotine Consumption to Personalised Intervention through
Genetic Studies
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Figure 1. (A) Hypothesis-free studies. Manhattan plot showing ﬁndings of a genome-wide association study (GWAS) that
looked at heaviness of smoking measured as cigarettes per day (CPD) and associated genetic signals. SNPs are plotted on
the x-axis according to their position on the chromosome, against the phenotype on the y-axis shown as log10 P value.
The strongest association with smoking quantity was found for the SNP rs1051730, followed by rs16969968. GWASs are
free from a priori hypotheses. Reprinted by permission from Macmillan Publishers Ltd on behalf of Cancer Research UK:
Nature Genetics 42(5), 441–447, copyright 2010. (B) Hypothesis-driven studies. Investigations with a speciﬁc genetic target
follow GWASs and previous investigations and employ strategies such as recall by genotype and Mendelian randomisation
(MR). The graph represents the distribution of the population (European ancestry) according to their phenotype (on the x-
axis). Homozygous individuals – wild type in yellow on the left and biallelic carriers of the risk allele in red on the right – reside
at its ends. (C) Neurobiology of smoking behaviour. Schematic drawing of the journey of cigarette smoke through the
airways to the lungs, the bloodstream, and, eventually, the brain. (D) Precise therapeutic intervention. Here is shown a
possible intervention to selectively address individuals with nicotinic acetylcholine receptors (nAChRs) comprising a D398N
/5 subunit (encoded by the minor allele). A speciﬁc agonist binds to the receptor and enhances its trafﬁcking of ions (Ca++,
Na+, and K+).The CHRNA5–CHRNA3–CHRNB4 Gene Cluster
The CHRNA5–CHRNA3–CHRNB4 gene cluster on chromosome 15 (at 15q25) encodes three
(/3, /5, b4) of the eleven (/2–7, /9, /10, b2–4) neuronal nAChR (Figure 2A) subunits. The
rs1051730 SNP in CHRNA3 is a coding, synonymous variant that does not result in an amino
acid change in the subsequent protein and is therefore unlikely to be of any functional
signiﬁcance; however, rs1051730 is highly correlated with rs16969968 in CHRNA5, a missense
mutation that results in the substitution of aspartate (D) to asparagine (N) at the 398th amino acid852 Trends in Neurosciences, December 2016, Vol. 39, No. 12
Glossary
Amino acid: the subunit that, joined
together with other amino acids,
forms a protein.
Candidate gene association
study: a study in which a speciﬁc
genetic variant is selected because of
its perceived biological relevance to
the phenotype of interest (i.e.,
hypothesis driven).
CHRN*: cholinergic receptor,
nicotinic*.
Ever-smokers: individuals who
either currently smoke or who used
to smoke.
Former smokers: individuals who
used to smoke but have stopped.
Genome-wide association study
(GWAS): examines the associations
of SNPs of the whole genome of a
cohort of individuals with the
phenotype of interest. The approach
has no a priori hypotheses.
Haplotype: combination of multiple
SNPs inherited together from a single
parent.
Homozygous: individuals are
homozygous when they have two of
the same allele at a given locus.
Knockout-mouse models: mice in
which a target gene has been
inactivated.
Never-smokers: individuals who
have never smoked
Pleiotropic effects: when a SNP or
gene inﬂuences more than one trait.
Polygenic risk scores: individual
scores reﬂecting the aggregate
genetic burden from collections of
common variants (which can be
formed by a variety of methods, the
simplest being summed allele
counts).
Positive allosteric modulator: a
ligand that binds to a receptor and
modulates its activity.
Smoking topography: how a
cigarette is smoked (i.e., the number
of puffs taken and the volume of
smoke inhaled per puff and per
cigarette).
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Figure 2. The Genetic Locus CHRNA5–CHRNA3–CHRNB4 Encodes the Subunits of a Nicotinic Acetylcho-
line Receptor (nAChR). (A) Simpliﬁed illustration of the human CHRNA5–CHRNA3–CHRNB4 gene cluster, which
encodes the /3, /5, and b4 nAChR subunits (not to scale). CHRNA5 is marked by rs16969968, which is in high linkage
disequilibrium with rs1051730 in CHRNA3. (B) Subunit composition of the heteromeric /5–/3–b4 nAChR. Nicotine is an
exogenous ligand for nAChRs; when nicotine binds to a nAChR, it modulates its trafﬁcking of cations.in the resultant /5 subunit protein (D398N). This variant is functional; in vitro studies have
demonstrated that /5 receptor complexes with the aspartic acid variant exhibit a twofold
greater maximal response to a nicotine agonist compared with /5 receptor complexes con-
taining the asparagine variant (i.e., the risk variant associated with smoking quantity and nicotine
dependence [6]). Interestingly, an analysis of gene expression has shown that the risk allele of the
rs1051730 SNP is associated with a lower level of expression of CHRNA5 in the brain and
peripheral blood mononuclear cells [7]. Animal studies have described the role of the /5 nAChR
subunit by investigating the /5 knockout-mouse model's phenotype; unfortunately, investi-
gation of the role of the /3 subunit in nicotine intake is challenged by the early postnatal lethality
that results from its genetic ablation.
From GWAS to Neurobiology
Smoke inhaled from a cigarette is a mixture of chemicals that travel through the airways to the
lungs. Nicotine is the primary addictive constituent of cigarette smoke; it is absorbed by the
alveolar epithelium and then circulates in the bloodstream. Nicotine is an exogenous ligand for
nAChRs and binds, after crossing the blood–brain barrier, to nAChRs ubiquitously expressed in
the brain (Figure 1C). nAChRs are ligand-gated ion channels that open in response to the binding
of acetylcholine and nicotine allowing trafﬁcking of cations (Ca++, Na+, and K+; Figure 2B).
Critically, our understanding of the neurobiology of smoking behaviours has been advanced by
GWASs, particularly through the identiﬁcation of how genetic variants that result in functional
changes in nAChRs lead in turn to behavioural outcomes.
Following the identiﬁcation of the association of the CHRNA5–CHRNA3–CHRNB4 gene cluster
with heaviness of smoking, an elegant series of experiments [8] established the underlying
mechanism linking this genetic variation to nicotine response. This work utilised an /5 knockout-
mouse model, which is analogous to individuals with reduced /5 receptor function (i.e., carriers
of the rs16969968 risk allele). Both wild-type and knockout animals showed the expected
inverted U-shaped dose–response curve for intravenous nicotine infusions with the difference
that knockouts responded more vigorously at high doses. While wild-type mice appeared to
titrate the delivery of nicotine dose (through self-administration) to achieve a consistent, desired
level, knockout mice did so to a considerably lesser extent, consuming greater amounts as the
dose increased.
Furthermore, [8] also showed that this effect could be ‘rescued’ in /5 knockout mice through
the injection of a lentivirus vector into the medial habenula (MHb), rescuing expression of /5
subunits in this region. The knockout mice did not appear to differ from wild-type mice in their
experience of the rewarding effects of nicotine, but the inhibitory effect of high nicotine doses on
the activity of reward circuitries observed in wild-type mice appeared to have been largelyTrends in Neurosciences, December 2016, Vol. 39, No. 12 853
abolished in knockout mice. This observation aligns with a previous study [9] where the
differential effects of nicotine dose on reward between /5 knockouts and wild-types was
illustrated using a conditioned place-preference task. In addition, a recent study in humans [10]
found an attenuated aversive response to intravenously administrated nicotine in overnight-
abstinent smokers who were carriers of the CHRNA5 rs16969968 risk allele genotype. The MHb
mainly projects to the interpeduncular nucleus (IPN) and [8] observed that diminished IPN activity
in response to nicotine was seen in knockout mice. In short, it appears that high doses of
nicotine stimulate the MHb–IPN tract through nAChRs containing /5 subunits and elicit
aversion, limiting further intake. This does not occur when /5 signalling is deﬁcient and
consequently the negative effects of nicotine are attenuated. Similarly, smokers carrying the
rs16969968 risk allele are therefore more likely to smoke more heavily than their counterparts
without the risk allele.
The study reported in [11] provides further evidence that the MHb acts as a gatekeeper for
nicotine intake. The authors manipulated the concentration of /5 and b4 in vitro while /3 was
kept constant, and as a result the cation conductance of the channel was altered. nAChR activity
changes according to the local electrostatic charge; therefore, the next step was to test the
nicotine-evoked currents in MHb neurons of wild-type mice and transgenic mice (called Tabac
mice) characterised by overexpression of b4. The authors [11] made patch-clamp recordings
after local delivery of nicotine and reported a dramatically higher ﬁring rate in Tabac mouse
neurons. The behavioural response observed in vivo also showed signiﬁcant changes in Tabac
mice compared with wild-type mice. Tabac mice exhibited reduced nicotine intake and a strong
preference for water rather than low-nicotine-concentration solutions in a two-bottle choice test.
By contrast, their littermate controls drank water and nicotine solution equally even at much
higher nicotine concentrations. Similarly, wild-type mice showed no preference for a nicotine-
conditioned versus saline-conditioned chamber while Tabac mice spent less time in the latter. In
addition, expression of the /5 D397N variant (corresponding to the human /5 variant D398N)
was elicited in MHb neurons by injecting a lentivirus vector in Tabac mice. The latter restored their
nicotine consumption and their two-bottle choice behaviour to a level comparable with wild
types. In summary, /5 and b4 compete in regulating nicotine intake: b4 overexpression
enhances MHb activity leading to aversion whereas induced /5 expression in Tabac mice
normalised nicotine consumption.
Measuring Smoking Behaviour
As we have seen, the ﬁrst major results of GWASs of smoking behaviours related to nicotine
dependence and smoking heaviness. These behaviours are conventionally quantiﬁed using self-
report measures such as the Fagerström Test for Nicotine Dependence (FTND) and the number
of cigarettes smoked daily (Box 1). Both the FTND and the number of cigarettes per day (CPD)
are valuable measures, but since they are based on self-reporting they are prone to subjective
errors. In addition, individuals differ in how they smoke a cigarette, varying in the number of puffs
taken and the volume of smoke inhaled per puff and per cigarette (smoking topography [12]);
therefore, cigarette smokers who consume the same CPD may differ in how much nicotine (and
other toxicants) they consume. Individuals homozygous for the major allele at rs16969968
reduce the volume of smoke inhaled per puff when the nicotine content of the cigarette is
increased; by contrast, carriers of the risk variant do not [13]. The lack of compensatory
behaviour in risk allele carriers when smoking cigarettes with higher levels of nicotine is
analogous to the reduced aversive effect of nicotine observed in /5 knockout mice [8].
How and what is measured to capture a phenotype (particularly for complex behaviours such as
smoking heaviness) can be critical to the strength of the genetic association observed. Smoking
studies that have used cotinine levels as a phenotype illustrate this. Nicotine consumed by a
smoker is metabolised principally into cotinine, which is therefore a biomarker for nicotine854 Trends in Neurosciences, December 2016, Vol. 39, No. 12
Box 1. Phenotyping of Smoking Behaviours
Phenotyping in humans can rely on subjective methods. Precise phenotypes such as proximate biomarkers better
capture genetically disposed interindividual differences in smoking. Here we provide a brief description of common
indicators used to quantify smoking dependence and heaviness.
CPD
CPD is the count of cigarettes smoked in one day from waking up to going to bed. This phenotype has been used in
several studies [2,50,51].
Questionnaires
 The FTND, or Fagerström Test for Cigarette Dependence (FTCD) as Fagerström renamed it in 2012 [52], assesses the
intensity of physical addiction to nicotine. The FTND is a six-item questionnaire. The total score range is 0–10 and a
higher score indicates higher dependence. Often, smokers with a score greater than 4 are deﬁned as dependent [1,6].
 The Questionnaire of Smoking Urges (QSU) provides a measure of current craving levels. The QSU is a ten-item
questionnaire. Each item requires a 1–5 response and a higher score indicates a greater urge to smoke.
Smoking Topography
Objective indicators such as number of puffs, puff volume, and the duration and velocity of the smoking of a cigarette
highlight interindividual differences in smoking behaviour. They can lead to different levels of biomarkers for similar levels
of CPD.
Biomarkers [53]
Biomarkers are directly correlated with the level of smoking and are measured objectively.
 Carbon monoxide (CO): Expired air CO levels in the breath are measured via a portable CO analyser. Smoking status
is usually conﬁrmed by a value of 10 parts per million (ppm). CO testing is a rapid, low-cost, and noninvasive method
for conﬁrming smoking status [54]. Alternatively, carboxyhaemoglobin (COHb) can be measured spectrophotometri-
cally in blood. Environmental sources of CO (e.g., car exhaust fumes) can contribute to the overall level of CO in the
organism.
 Nicotine: Nicotine levels can be measured in urine, saliva, and blood by means of gas or high-performance liquid
chromatography and immunoassays. However, nicotine has a short half-life and is therefore suited to capturing
nicotine consumption only in the 8–12 h before testing.
 Cotinine: Most (90%) nicotine is broken down into cotinine. The half-life of cotinine is relatively long (16 h) and it is
therefore generally preferred as a biomarker of nicotine intake. Urine tests allow discrimination between smokers and
non-smokers while more accurate measures, in saliva and blood, are performed as for nicotine, by means of gas or
high-performance liquid chromatography and immunoassays.consumption. It can be reliably detected in the serum, urine, and saliva of smokers (Box 1) [14]. In
the study reported in [15], the authors showed that the variants in the CHRNA5–A3–B4 gene
cluster are more strongly associated with levels of cotinine than CPD. This was subsequently
conﬁrmed in an extensive meta-analysis: there is a much stronger signal for the association
between the CHRNA5–A3–B4 genotype and heaviness of smoking when this is captured by
cotinine levels (4% of phenotypic variation explained) rather than CPD (1% variation explained).
Interestingly, the association with cotinine levels remains when CPD is statistically adjusted for in
the analysis [15,16].
These ﬁndings highlight the need for more precise phenotypic measures. However, collecting
detailed phenotypic data depletes resources and may not be feasible for large cohorts of
individuals. A strategy to select a smaller sample is recall by genotype. For example, in 200
individuals of European ancestry from the general population, we would expect to ﬁnd only 32
homozygous for the risk variant rs16969968 (AA, asparagine/asparagine) and 78 homozygous
for the wild-type variant (GG, aspartate/aspartate) [17]. If in-depth phenotyping is time consum-
ing and expensive, and collecting data on 200 participants is at the limit of available resources,
selectively recruiting 100 minor homozygotes and 100 major homozygotes from a larger genetic
screen before conducting in-depth phenotyping is likely to be a far more powerful and efﬁcient
use of resources, given the low cost of genotyping. We know that current smokers smoke oneTrends in Neurosciences, December 2016, Vol. 39, No. 12 855
more cigarette and show a 138 nmol/l mean increase in cotinine levels for each copy of the
rs16969968 minor allele that they may carry [16]. By recalling participants according to
rs16969968 genotype (i.e., the two homozygote groups), we can capture the greatest pheno-
typic difference in smoking heaviness resulting from genetic difference at the CHRNA5–A3–B4
locus (Figure 1B). As we see in the next section, this approach captures many of the features of a
randomised experimental design and therefore any potential confounding factors should be
randomly distributed across the sample because it has been selected solely according to
genotype.
Causal Analyses and Mendelian Randomisation (MR)
The robust association of variants in the CHRNA5–A3–B4 gene cluster with smoking intensity
phenotypes makes variation at this locus a valuable tool for investigating the causal effects of
tobacco exposure. Although many of the harmful effects of smoking, such as lung cancer and
cardiovascular disease, are well documented (http://www.surgeongeneral.gov/library/reports/
50-years-of-progress/full-report.pdf), tobacco use is associated with many other conditions for
which causal links remain to be established. For example, in the UK smoking rates are higher in
individuals with a mental health condition – estimated to be 33% compared with 19% in the
general population (http://www.ash.org.uk/ﬁles/documents/ASH_120.pdf). In addition, the
mechanisms through which smoking causes some diseases, such as cardiovascular disease,
are not yet fully understood. Much of the evidence regarding the health effects of smoking comes
from observational data. Causal inference from observational data can be problematic because
smoking is associated with a range of lifestyle and demographic factors including
socioeconomic status, diet, and other substance use. Therefore, we cannot be certain that
associations are due to smoking itself or to these other factors. For example, maternal smoking
during pregnancy is linked with numerous offspring outcomes but confounding by familial
factors (including genetic factors) is likely to explain some of these associations [18]. Further-
more, individuals may alter their smoking behaviour in response to ill health, so reverse causality
may also inﬂuence these observational associations.
The problems of confounding and reverse causality in the investigation of the causal effects of
smoking can be reduced by using variants in the CHRNA5–A3–B4 gene cluster as proxies for
smoking heaviness in MR analyses (Box 2). In contrast to direct measurement, germline
genotypes reliably associated with risk factors can act as proxy measures of exposure, offering
several advantages: genotypes are relatively easy to measure precisely, are stable through time,
are largely immutable, and are not correlated with confounding factors, given the mechanisms of
Mendelian inheritance [19,20].
The study reported in [21] provides a useful example of how rs16969968 can be used in an MR
approach. The authors found that the smoking heaviness-increasing allele of rs16969968 was
associated with lower offspring birthweight in women who smoked during pregnancy but not in
women who did not smoke during pregnancy. This conﬁrmed previous ﬁndings that smoking in
pregnancy is linked to reduced offspring birthweight and conﬁrmed that this association is likely
to be causal. In a similar manner, [22] demonstrates that the smoking heaviness-increasing allele
of rs16969968 is associated with lower body mass index in current and former smokers but
not in never-smokers, suggesting that heavier smoking causally lowers body weight. The
ﬁnding has been replicated and extended to other measures of adiposity (e.g., waist circumfer-
ence) in subsequent MR analyses [23–25]. Similar analyses have shown that smoking leads to
higher resting heart rate and may adversely affect kidney function, as it leads to higher estimated
glomerular ﬁltration rate [25,26], as well as all-cause mortality [27].
MR has also highlighted observational associations that may not be causal. Despite strong links
between smoking and mental health, MR studies have not found evidence that the minor allele of856 Trends in Neurosciences, December 2016, Vol. 39, No. 12
Box 2. MR Analysis
MR analysis is a type of instrumental variable analysis that uses genetic variants (either individually or combined in a
genetic risk score) as proxies for measured exposures (in this case smoking) in observational datasets (see Figure 3 in
main text) [19]. As independent heritable units (be they speciﬁc variants, structural changes, or genetic risk scores) are
inherited independently of the environment, they should not be associated with other factors that confound the
relationship between exposures and outcome measures. In addition, germline genetic changes reﬂect life-course
alterations and (while these effects may be variable through time) they will be less susceptible to reverse causality.
To be a suitable instrument for a MR analysis, a genetic variant should be: (i) robustly associated with the exposure we are
interested in; (ii) associated with the outcome measure only through the exposure of interest (i.e., it does not have
pleiotropic effects); and (iii) not associated with factors that confound the association between exposure and outcome.
It is important to note that new methods for the undertaking of MR analyses are able to account for violations of these
assumptions and to quantify the extent of the likely biases induced by failures to satisfy them [55,56].
While it is not possible to fully test these assumptions, knowledge of the biology of the CHRNA5–CHRNA3–CHRNB4
gene cluster, including the identiﬁcation of the functionally signiﬁcant SNP rs16969968 and its role in determining
response to nicotine, strengthens the validity of variants in this gene cluster as instruments for MR analyses.
The rs16969968 (or rs1051730) variant has been used to investigate whether associations between smoking and several
health outcomes are causal. As the variant is associated with smoking heaviness rather than smoking initiation, it is used
as an instrument for smoking heaviness within smokers and ﬁndings of MR studies using this variant do not directly tell us
whether being a smoker causes a particular disease. However, using rs16969968 as an instrument for smoking
heaviness in smokers provides evidence about whether smoking has a dose–response effect on an outcome (which
is a key criterion for causality). MR analyses using this variant are stratiﬁed by smoking status (never- and ever-smokers or
never-, former, and current smokers) and we test for an interaction between genotype and smoking status. As there are
no effects of the variant on smoking heaviness in never-smokers, this group can be used to test the assumption of no
pleiotropy. If an association with the outcome of interest is observed in never-smokers, it suggests that the variant is
operating through a pathway other than smoking and that the MR assumptions may be violated.
Confounders 
e.g., diet
rs16969968
Smoking 
heaviness Outcome
Confounders 
e.g., diet
rs16969968
Smoking 
heaviness Outcome
(A) Ever smokers
(B) Never smokers
Figure 3. Mendelian Randomisation Using rs16969968 in CHRNA5 as an Instrument for Smoking Heaviness.
(A) In Mendelian randomisation analyses, rs16969968 is used as a proxy for smoking heaviness in ever-smokers. While the
association between smoking heaviness (e.g., number of cigarettes smoked per day) and the outcome of interest may be
confounded by lifestyle and demographic factors (e.g., diet), the association between rs16969968 and the outcome should
not be. The outcome of interest may inﬂuence smoking heaviness (reverse causality) but will not inﬂuence rs16969968
genotype. (B) As never-smokers do not smoke, any association between genotype and outcome cannot be operating
through effects of the genotype on smoking.
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rs16969968 is associated with higher levels of depression in smokers [28–30], suggesting that
smoking does not cause depression. Lack of associations of rs16969968 with blood pressure,
serum lipids, and glucose levels indicate that smoking may not causally inﬂuence these
cardiometabolic traits [25,26].
Importantly, evidence for causal effects of smoking does not have to come from formally
conducted MR studies. As discussed above, variants in the CHRNA5–A3–B4 gene cluster
were identiﬁed in GWASs of smoking-related diseases [e.g., lung cancer, chronic obstructive
pulmonary disease (COPD)]. While there was debate about a possible direct effect of variants in
the cluster on these diseases, it is now widely accepted that these variants appeared in these
GWASs because these diseases are caused by smoking. GWASs can therefore provide us with
important insights into whether environmental exposures may affect disease [31].
Recently, a GWAS of schizophrenia led to renewed interest in the relationship between smoking
and schizophrenia. Smoking rates are high among individuals diagnosed with schizophrenia but
it is unclear whether this link is causal and, if so, in which direction this operates. The identiﬁcation
of the CHRNA5–A3–B4 cluster in the recent GWAS of schizophrenia [32] suggests either that
variants in this gene cluster cause both schizophrenia and heavier smoking independently or that
heavier smoking is a causal risk factor in the development of schizophrenia [33–35]. As the
GWAS was not conducted stratiﬁed by smoking status, it is difﬁcult to distinguish between these
two possibilities; however, a recent MR analysis [29], which was stratiﬁed by smoking status,
provides supportive evidence for a causal effect of smoking on schizophrenia. They found that
the minor allele of rs1051730 was associated with higher odds of being prescribed antipsychotic
medication in ever-smokers but not in never-smokers in the Copenhagen General Population
Study. A similar trend was observed for schizophrenia diagnosis. Other observational studies
and meta-analyses have provided convergent evidence for the association between schizo-
phrenia (and psychotic illness more generally) and smoking behaviour [36–38].
One limitation of the MR approach is that it typically requires very large sample sizes, because
genetic variants for common traits generally only explain a very small proportion of phenotypic
variation. Therefore, many MR studies combine data from multiple studies to increase their
power to detect effects (e.g., [28]). A further solution is to perform MR analysis on samples of
individuals recalled and phenotyped on the basis of genotype. As discussed above, this
maximises genetic differences (and therefore differences in phenotypic exposure) between
individuals. In the case of CHRNA5–A3–B4, selecting only homozygotes for rs16969968
increases the power to detect causal effects of smoking [17]. Investigating the causal effects
of the genotype–phenotype relationship is key to progress in the identiﬁcation of human genetic
targets for smoking treatment.
From Genetics to Therapeutics
The treatment of nicotine dependence remains a signiﬁcant unmet medical need given the
limited efﬁcacy of behavioural and pharmacological [e.g., nicotine replacement therapy (NRT),
varenicline] treatments. Most clinical studies of new chemical entities that may act as smoking
cessation agents undertaken since 2012 have not progressed to the clinic due to lack of safety
and/or efﬁcacy [39]. At present in the USA there are only two new molecular agents, besides
variations on NRT formulations, that are in clinical efﬁcacy studies for smoking cessation. The
ﬁrst is a Phase II study looking at the efﬁcacy of AZD8529, an mGluR2 positive allosteric
modulator, being conducted by the National Institutes of Health (NIH)/National institute on
Drug Abuse (NIDA) [NIDA (2016) The study of AZD8529 for smoking cessation in female
smokers, ClinicalTrials.gov]. The second is a study directed by Cerecor, Inc. testing a kappa
opioid receptor antagonist, CERC-501. Consistent with previous clinical trials, both of these
mechanisms were identiﬁed and validated in preclinical rodent and primate intravenous nicotine858 Trends in Neurosciences, December 2016, Vol. 39, No. 12
Outstanding Questions
Will human GWASs, in parallel with
experiments in preclinical (e.g., rodent)
models and human studies, allow us to
go beyond the known neurobiology of
smoking behaviour and provide genu-
inely novel mechanistic insights?
Will biomarkers (e.g., cotinine) allow us
to both gain information about the role
of target genes and anticipate the
response to treatments targeting the
corresponding gene products?
Will insights into gene-to-phenotype
causal relationships lead to novel treat-
ments for smoking cessation?
Do schizophrenia and heavy smoking
share an underlying genetic liability or is
smoking causally related to schizo-
phrenia risk or other mental health
conditions?
Will increasing the reward-attenuating
properties of nicotine enhance treat-
ment response in a well-deﬁned popu-
lation of smokers?self-administration models. This reﬂects our current reliance on preclinical models of aspects of
nicotine dependence and their ability to identify and differentiate new mechanisms relevant in a
manner that translates into clinical efﬁcacy in human smokers.
Human genetics ﬁndings in nicotine dependence and smoking heaviness may reveal novel
targets for medication development or even highlight novel brain substrates within which such
targets are expressed. However, neither of the studies described above appears to have utilised
human genetics to identify the target or to set inclusion criteria and thereby stratify patient
populations to identify those most likely to demonstrate a positive response to treatment [40,41].
Nevertheless, it is clear that, relative to other substance use disorders (and more broadly across
domains of psychiatry), human genetics approaches such as GWASs have proved successful in
identifying allelic variations that inﬂuence vulnerability to nicotine dependence. There is emerging
evidence that a stratiﬁed medicine approach utilising CHRNA5 genetic biomarkers may improve
patient responsiveness to NRT [10,42–44]. For example, [42] describes two randomised
cessation trails in which it was found that the efﬁcacy of NRT varied with rs16969968 genotype
while the efﬁcacy of varenicline did not, as subjects responded to varenicline regardless of
CHRNA5 rs16969968 genotype.
The /5*-containing nAChRs impacted by CHRNA5 variation may represent an important target
for medication development. Considering that CHRNA5 risk alleles result in decreased function
of /5* nAChRs incorporating the variant subunits [6,45,46], it is reasonable to predict that novel
chemical entities that enhance activity of a5* nAChRs will decrease tobacco use [8,10].
Moreover, the neuronal circuits in which /5* nAChRs that regulate nicotine intake may reside,
and other genes associated with risk of nicotine dependence, are also likely to contain novel
targets for medication development. Studies in patients with the rs16969968 risk variant
suggest that diminished activity of the /5-containing nAChR leads to a delay in response to
NRT and smoking cessation [5,11]. Given the observed reduction in activity of the D398N /5
nAChR, it seems logical to begin the identiﬁcation of selective ligands that enhance nAChR
function (i.e., agonists; Figure 1D). However, the highly conserved nature of the orthosteric site
among nicotinic acetylcholine receptor subunits makes it challenging to identify orthosteric
ligands with optimal selectivity and physiochemical properties [47]. Therefore, an alternative
approach is to look for selective positive allosteric modulators of the /5 subunit, perhaps by
targeting key habenular circuits. This could be achieved either by restoring appropriate cholin-
ergic tone and the aversive or reward-attenuating properties of nicotine in a genetically insensi-
tive population or by increasing it in the normal population to reduce daily nicotine intake [5].
Concluding Remarks and Future Perspectives
GWASs have highlighted the important role of the CHRNA5–A3–B4 gene cluster in smoking
heaviness. Further studies have highlighted that the same gene cluster is also associated with
vulnerability to many smoking-associated diseases such as COPD and lung cancer
[1,2,6,48,49]. Whether the same genes are associated with mental health is still disputed,
although the latest ﬁndings suggest that smoking heaviness and schizophrenia share some
genetic liability [35,38].
Early studies on the CHRNA5–CHRNA3–CHRNB4 cluster and smoking behaviours relied on
self-reported phenotypes (such as CPD) that display great variance, but subsequent studies
have replicated the gene-to-phenotype associations with novel measures and analysis tools that
allow a further step towards understanding the directionality in the relationship between genes
and behaviour.
The advances in phenotyping (e.g., by employing precise biomarker assessments), together
with the fast development of DNA and RNA sequencing technologies and powerful analyticalTrends in Neurosciences, December 2016, Vol. 39, No. 12 859
tools, are making GWASs easier to perform and more informative. Further genomic mapping of
smoking phenotypes will clarify the role of the CHRNA5–A3–B4 gene cluster and, more broadly,
of sets of variants and may lead to the development of polygenic risk scores for such complex
traits and, ultimately, clarify the pathways that may be shared by multiple phenotypes. Genetic
variants emerging from GWASs that inﬂuence smoking behaviour and tobacco-related dis-
eases, and that are validated by independent studies, could inform individual-tailored treatments
(see Outstanding Questions) and pave the way to targeted genetic therapeutic interventions for
smoking cessation, ultimately reducing the burden of tobacco-related diseases.
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